Adding Hormone Therapy to PORT Might Not Benefit Patients with Recurrent Prostate Cancer and PSA of 0.5 ng/mL or Less By Ogkologos - March 5, 2026 158 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the POSEIDON meta-analysis of the MARCAP consortium Source RELATED ARTICLESMORE FROM AUTHOR ESMO Joins WHO Global Clinical Trials Forum to Strengthen Global Oncology Research Ecosystems EMA Recommends Extension of Therapeutic Indications for Enfortumab Vedotin Selinexor plus Ruxolitinib Reduces Spleen Volume, but Does Not Improve Symptom Responses Over Ruxolitinib in Patients with JAK Inhibitor-Naïve Myelofibrosis MOST POPULAR Sofi Leota Was Diagnosed With Breast Cancer At 23. Two Years... July 23, 2020 Wales: 4 in 10 with possible cancer symptoms didn’t contact GP June 17, 2021 Pastor Opens Homeless Shelter And Moves In To Raise Money For... December 29, 2021 Analysis Shows Women with High Breast Cancer Recurrence Scores Benefit from... October 24, 2019 Load more HOT NEWS New Study Says At-Home Cancer Care May Lead to Fewer Hospitalizations... Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... NALIRIFOX Improves Survival Compared with Nab-paclitaxel Plus Gemcitabine in First-Line Treatment... Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?
